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Background: Prior work showed that whole blood, plasma, and serum injections are damaging to the neonatal
rodent brain in a model of intracerebral/periventricular hemorrhage. Thrombin alone is also damaging. In adult
animal models of hemorrhagic stroke, the protease-activated (thrombin) receptor PAR1 mediates some of the brain
damage. We hypothesized that PAR1 interference will reduce the adverse effects of blood products on immature
rodent brain and cells.
Results: Cultured oligodendrocyte precursor cells from rats and mice were exposed to blood plasma with and
without the PAR1 antagonists SCH-79797 or BMS-200261. In concentrations previously shown to have activity on
brain cells, neither drug showed evidence of protection against the toxicity of blood plasma. Newborn mice (wild
type, heterozygous, and PAR1 knockout) were subjected to intracerebral injection of autologous whole blood into
the periventricular region of the frontal lobe. Cell proliferation, measured by Ki67 immunoreactivity in the subventricular
zone, was suppressed at 1 and 2 days, and was not normalized in the knockout mice. Cell apoptosis, measured
by activated caspase 3 immunoreactivity, was not apparent in the subventricular zone. Increased apoptosis in
periventricular striatal cells was not normalized in the knockout mice.
Conclusion: Interference with the thrombin-PAR1 system does not reduce the adverse effects of blood on germinal
cells of the immature rodent brain. PAR1 interference is unlikely to be a useful treatment for reducing the brain damage
that accompanies periventricular (germinal matrix) hemorrhage, a common complication of premature birth.
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Cell proliferationBackground
Hemorrhage in the periventricular germinal tissue of
developing brain (often called germinal matrix or peri-
ventricular hemorrhage, PVH) is a major complication
of preterm birth before 32 weeks gestational age [1].
PVH is associated with suppressed proliferation of the
periventricular germinal cell populations in human in-
fants [2]. The same suppression occurs in an experimen-
tal mouse model [3]. It is important to understand this* Correspondence: marc.delbigio@umanitoba.ca
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unless otherwise stated.phenomenon because it may adversely affect subsequent
brain development and contribute to the neurological
complications suffered by premature infants [4]. Blood
injections have been shown to damage immature mouse
brain; much of the effect seems to be attributable to the
plasma proteins thrombin and plasmin [5,6]. Using cul-
tured rat subventricular zone (SVZ) cells and oligo-
dendrocyte precursor cells (OPC) we showed that blood
plasma and blood serum, as well as purified thrombin,
plasmin, and kallikrein had similar toxic effects on cell
proliferation, migration, and differentiation [7].
Prothrombin is a serine protease contained in blood
plasma. Following activation, thrombin has a central inentral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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mation and acts as a mitogen for some cell types [8]. In
adult animal models of brain hemorrhage, thrombin
plays a role in the resulting brain damage [9]. Signaling
through one of the major G-protein coupled receptors,
protease activated receptor 1 (PAR1; properly called co-
agulation factor II receptor, F2r), appears to mediate the
process [10,11]. Interference with this pathway has been
proposed as a potential target for therapeutic interven-
tion following brain hemorrhage. Following blood injec-
tion into 1-day-old mouse brains, the thrombin inhibitor
hirudin was capable of reducing inflammation and brain
cell death at 2 days, but the long-term outcomes were
unchanged [6]. In the rat brain cell model system, hirudin
reduced the cell death caused by thrombin but not the
suppression of cell proliferation [7]. Plasmin, which was
shown to be damaging in the above-mentioned mouse and
cell culture models, can also act through PAR1 [12].
Cultured OPC express high levels of PAR1 messenger
RNA with expression declining as the cells mature, and
they show PAR1 and PAR2 immunoreactivity at the O4+
stage of maturation [13]. Cultured OLN-93 oligodendro-
cyte cells also express PAR1 and PAR3, but not PAR2 or
PAR4 [14]. Thrombin stimulation causes increases in
intracellular calcium ion in SVZ-derived OPC and the
effect is mediated by PAR-1 activation [15]. SCH-79797
suppresses PAR1 signaling in primary astrocyte cultures
[16,17] and in hippocampal slice cultures [18] and it
protects against brain injury in rats [19]. BMS-200261
interferes with PAR1 in cultured astrocytes [12] and re-
duced infarct volume in a mouse model of focal cerebral
ischemia [20]. We hypothesized that interference with
the PAR1 will reduce the germinal cell damage associ-
ated with blood injection into the immature rodent
brain. The first aim was to determine if chemical PAR1
antagonists could reduce damage to cultured mouse and
rat OPC exposed to blood plasma. The second aim was
to compare periventricular SVZ damage following blood
injection into brains of newborn wild type, heterozygote,
and PAR1 knockout mice. In mice this region rapidly
involutes between birth and 8 days age [21]. Cells born
here are destined to become oligodendrocytes and as-
trocytes in the cerebrum and neurons in the olfactory
bulb [22-25].
Results
OPC cultures exposed to blood plasma and PAR1 inhibitors
Both the rat and mouse OPC cultures expressed pre-
dominantly oligodendrocyte lineage markers, including
A2B5 at 6 hours, O4 for up to 3 days, and CNPase and
MBP after 6 days. In the absence of plasma, exposure of
rat OPC to SCH-79797 at concentrations of 0.05 to
5 μM had no obvious affect on LDH release, while 10-
50 μM was associated with a 2-fold increase in LDHrelease (P < 0.05). In the absence of plasma, exposure of
rat OPC to BMS-200261 at 0.05 to 50 μM had no obvi-
ous affect on LDH release, 100 μM was associated with
a 2-fold increase in LDH release, and 200 μM was asso-
ciated with a 4-fold increase in LDH release (p < 0.05;
Figure 1). Exposure of rat OPC to plasma at 1:1000 con-
centration was associated with a 2-fold increase in LDH
release, 1:250 was associated with a 3.5-fold increase in
LDH release, and 1:100 was associated with a 6-fold in-
crease in LDH release. Combined with plasma at 1:1000,
1:250, or 1:100 concentrations, SCH-79797 showed no
evidence of protection at 0.05-5 μM concentrations.
Combined with plasma at 1:250 concentration, 10-50 μM
SCH-79797 accentuated the toxicity (4-fold increase in
LDH release). Combined with plasma at 1:250 concentra-
tion, BMS-200261 showed no evidence of protection at
0.05-10 μM while 25-200 μM accentuated the toxicity
(4-fold increase in LDH release) (Figure 2). Cell prolifera-
tion measured by BrdU incorporation was not normalized
with the drug therapy (all comparisons p > 0.5).
The mouse OPC experiment was abbreviated with
avoidance of the high concentrations of drug that were
independently toxic to the rat OPC. Exposure to blood
plasma at 1:250 concentration was associated with a
5-fold increase in LDH release from mouse OPC. Ex-
posure of mouse OPC to SCH-79797 at 5-10 μM caused a
slight increase in LDH release; combined with plasma at
1:250 the toxic effect was doubled (10-fold increase LDH
release). Exposure of mouse OPC to plasma at 1:250 con-
centration combined with BMS-200261 at 0.5 and 2 μM
reduced the LDH release in comparison to plasma alone,
however the difference was not statistically significant
(194 ± 88 vs. 51 ± 18 U; p = 0.22).
PAR1−/− mice with autologous blood injection into brain
Blood injected mice suffered no mortality and there
was no obvious behavioral consequence. In intact
and sham injected control mice (wild type, heterozy-
gote, and PAR1−/−), Ki67 was expressed by 23.5 ± 4.8% of
SVZ cells along the frontal horns of the lateral ventricles.
There were no significant differences between the con-
trols at the two time points or between genotype. Only
scattered cells outside of the SVZ were Ki67 positive. In
the controls, activated caspase 3 immunoreactivity was
negligible. Microglia with delicate processes that expressed
Iba1 were scattered throughout the cerebrum. However,
within the SVZ only a small proportion (1.4 ± 0.2%) of cells
expressed Iba1. There were no statistically significant dif-
ferences across genotype or time (all p > 0.4).
Following blood injection into the right periventricular
region, blood entered the frontal horns of the lateral
ventricles, which enlarged slightly. Ki67 expression by
proliferating cells decreased in the ipsilateral SVZ. In
comparison to controls, the differences were statistically
Figure 1 Bar graph showing effects of PAR1 inhibitors on rat oligodendrocyte precursor cells (OPC) cultured in serum-free defined
media. Cell death was measured by LDH release (optical density units; mean ± SEM). At high concentrations both SCH79797 and BMS20061 were
toxic to the cells (*p < 0.05).
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hour wild type mice (p < 0.005; Figure 3A-C). Follow-
ing blood injection, suppressed Ki67 expression in the
PAR1−/− mice with did not differ from the wild type
or heterozygous mice at either time point (p = 0.40 to
0.95). In the contralateral SVZ the only significant differ-
ence in Ki67 expression after blood injection was a
slightly lower percentage in the PAR1−/− mice at 24 hours
(19.3 ± 2.5% vs. 28.4 ± 5.8% in heterozygote control,Figure 2 Bar graph showing effects of plasma alone and in combinat
(OPC) in culture. Cell death was measured by LDH release (optical density
defined culture media was toxic to OPC as indicated by increased LDH rele
BMS20061 at any dose. Control values (no plasma) were significantly less th
differences between treatment groups (all comparisons p > 0.5).p = 0.0418; 26.6 ± 3.1% in wild type control, p = 0.136);
at 48 hours there were no differences between groups
(p > 0.7).
In comparison to mice without blood injection, acti-
vated caspase 3 immunoreactive cells were significantly
increased in the heterozygous mice at 24 hours (and
the wild type mice at 48 hours after blood injection
(Figure 4A-C). Careful evaluation of the H&E stained
sections demonstrated only very rare karyorrhecticion with PAR1 inhibitors on rat oligodendrocyte precursor cells
units; mean ± SEM). Plasma at 1/250 concentration added to the
ase. There was no evidence for protection with SCH79797 and
an all groups (*p < 0.05) and there were no statistically significant
Figure 3 Cell proliferation in immature mouse brain following periventricular blood injection. A - Ki67 nuclear immunoreactivity (brown
stained nuclei; hematoxylin counterstain) is prominent in the frontal periventricular subventricular zone (SVZ, arrow) of control (i.e. no blood injection)
mice from all three genotypes (this example is wild type). B – Following blood injection, some of which extends into the frontal horn of the
lateral ventricle (arrow), Ki67 immunoreactivity in the SVZ is reduced (this example is a PAR1 knockout). C – Quantitative analysis (ANOVA)
shows the proportion of Ki67 immunoreactive cells in the SVZ was significantly reduced in the 24-hour heterozygous (Het; *p = 0.0050) and
the 48-hour wild type (WT; *p = 0.0054) mice; the reduction also approached significance in the 48-hour knockout (KO; p = 0.0577) in comparison to
controls. Bar = 100 μm.
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striatum and very few were in the SVZ. This is similar to
our previous observation in mice that blood injection
substantially suppresses SVZ proliferation but has only
minor effects on cell death [3]. The PAR1−/− mice withblood injection did not differ from controls that had not
received blood injection, and they had significantly fewer
caspase 3 positive cells in the periventricular striatum
(but not SVZ) at 48 hours in comparison to blood-
injected wild type mice (p = 0.0028). The general trends
Figure 4 Cell death in immature mouse brain following periventricular blood injection. A - Activated caspase 3 immunoreactivity is extremely
rare in the SVZ of control mice (brown stained cells; hematoxylin counterstain) (arrow; this example is wild type). B – Following blood injection,
activated caspase 3 immunoreactivity is prominent in the striatum (arrow) but very rare in the SVZ (this example is a PAR1 knockout). C – Quantitative
analysis shows a statistically significant increase in caspase 3 immunoreactive cells in the striatum of most groups in comparison to intact
control (p < 0.007), but there were no significant differences between the blood-injected groups (all p > 0.15; Wilcoxon method). All micrographs
were taken at 400× magnification. Bar = 100 μm.
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bral white matter, but none of the differences were statis-
tically significant (all p > 0.2).
Following blood injection, the quantity of Iba1 ex-
pressing cells in the SVZ was significantly lower in most
groups in comparison to intact baseline (e.g. 0.6 ± 0.2%
in 48 h blood-injected heterozygote vs. 1.4 ± 0.2% in in-
tact control; p = 0.0326). However, there were no differ-
ences between genotypes following blood injections (all
comparisons >0.13) and considering the very low base-
line values it is not clear that the decrease after blood in-
jection is biologically important. There was no numeric
change in the cerebral white matter following blood in-
jection in any group. However, the immunoreactive cells
tended to be larger suggesting that the microglia had
reacted to the needle insertion and/or blood injection.
Discussion
Blood, blood plasma, blood serum, plasmin, and throm-
bin were previously shown in our laboratory to suppress
proliferation and cause cell death in rat OPC in a dose-
dependent manner [7]. Neonatal mouse brain showed
comparable sensitivity in vivo following injection of
blood components including suppressed cell prolifera-
tion in the SVZ [3,5,6]. PAR1 has repeatedly been shown
to play an important role in hemorrhagic brain damage
in adult experimental models [9,10,26,27]. However,
based on the experiments presented here, we reject the
hypothesis that PAR1-mediated signaling is critical to
the SVZ changes that follow brain hemorrhage. Blood
plasma was applied to OPC at a concentration previ-
ously shown to cause a combination of reduced cell pro-
liferation and increased cell death [7]. At concentrations
previously shown to have activity in astrocytes [12,17]
and hippocampal slices [18], the selective peptide (BMS-
200261) and nonpeptide (SCH-79797) inhibitors of the
PAR1 receptor failed to protect mouse or rat OPCs
against the toxic effect of blood plasma, despite the fact
that these cells are known to express PAR1 and respond to
its activation [13,15]. The chemicals used have both been
shown to suppress PAR1 signaling in cultured brain cells
[12,16,17] and to protect against brain injury in adult ro-
dents [19,20]. At high concentrations the PAR1 inhibitors
themselves were toxic. SCH-79797 (200 nM) has been
shown to cause apoptosis in 3 T3 fibroblast cell cultures
through PAR1 independent mechanisms [28]. One likely
reason why the PAR1 inhibitors were not protective is the
fact that blood plasma contains many other injurious con-
stituents that act through non-PAR1 mediated mecha-
nisms. We have previously shown in this OPC culture
model, that cells are also suppressed and killed by comple-
ment 5a, gamma amino butyric acid, and kallikrein [7].
In the neonatal mouse experiment, injection of autolo-
gous blood into the periventricular region of the braincaused a substantial suppression of proliferating SVZ
cells as well as a slight increase in apoptosis among non-
SVZ periventricular cell populations. This is similar to
the findings in our previous experiments using this
model system [3,5]. In the current experiment, the dam-
aging effect of blood on the periventricular SVZ was not
modified through selective omission of the thrombin
receptor PAR1. However, there was a decrease in cas-
pase 3 activation (presumably an indicator of apoptosis)
within the striatum, where the cells are more mature.
Adult PAR1−/− mice have less brain damage following
intracerebral injection of thrombin [10], transient occlu-
sion of the middle cerebral artery [20,29], global ische-
mia [30], and following cortical stab injury [26]. The
absence of a protective effect on SVZ cells in vivo might
also relate to the distribution of PAR1 in the developing
brain. During mouse development, PAR1 plays an im-
portant role in vasculogenesis and hemostasis [31], as
well as more focal involvement in neural tube closure
[32]. Reports on expression of PAR1 mRNA in develop-
ing rodent brain are not entirely consistent. In one
mouse brain database, PAR1 is expressed mainly on
endothelial cells and a subpopulation of SVZ cells on
gestational day 15, while on postnatal day 7 most PAR1
expression is in neurons [33]. In another mouse data-
base, ganglionic eminence progenitors are reported to
have high expression on gestational day 16 [34]. In the
rat, PAR1 mRNA is abundant in the periventricular re-
gion of brain at gestational day 14 and the day of birth,
while discrete neuronal expression is predominant by
postnatal day 7 [35].
Shortcomings must be considered. Despite the value
of mouse experiments for genetic manipulation, new-
born mouse is not the ideal animal model for studying
germinal matrix damage following PVH. In humans,
premature birth at 24–28 weeks gestation is the period
of greatest risk for PVH [1]. In some respects the post-
natal day 6–7 mouse brain is comparable to human
brain at that stage of development [36]. However, in
terms of relative volume, the ganglionic eminence (the
largest SVZ concentration) of the gestational day 17
mouse and gestational week 24 human are more com-
parable [2,21]. Furthermore, the mouse SVZ is much less
complex than in primates [37,38]. The proportion of
proliferating cells in the human ganglionic eminence
SVZ at 24 weeks gestation is approximately 60% [2]. In
neonatal mice the proportion is much lower at ~23%.
We focussed on PAR1 because most experimental evi-
dence shows a role for that receptor in brain damage re-
lated to hemorrhage. However, PAR2 [39], PAR3 [40],
and PAR4 [41] also appear to play roles in microglial ac-
tivation and neuron degeneration that follow experimen-
tal brain injury. Small sample sizes must be considered.
In the OPC culture experiments, toxicity of the PAR1
Mao and Del Bigio Journal of Negative Results in BioMedicine  (2015) 14:3 Page 7 of 10inhibitors was not strictly dose dependent suggesting
some unexplained variation in the system. However, the
inhibitors showed no trends suggesting protection. Des-
pite small sample sizes in the mouse experiment the
basic cellular responses to blood injection (reduced SVZ
proliferation, increased cell death in the adjacent stri-
atum) were in the predicted directions and there were
no trends suggesting that the PAR1 knockouts had any
reduced damage in the SVZ. Failing to identify any posi-
tive effects in two kinds of experiments, analysis of
PAR1 role in these model systems was not exhaustive,
however rejection of the hypothesis is reasonable.
Conclusions
We conclude that blocking the thrombin-PAR1 system
does not reduce the adverse effect of blood and blood
plasma on SVZ cells and OPC of the developing rodent
brain, despite the published evidence for expression and
functionality of PAR1 in these cell populations. These
experiments might not exclude an important role of
thrombin, but they do show that thrombin-induced
damage through PAR1 is not the exclusive mode of in-
jury following exposure to blood plasma, which contains
many active and potentially toxic proteins and catabolic
products [42]. Despite published evidence in adult model
systems, protection of immature brain against the ad-
verse effects of hemorrhage by interference of a single
molecular pathway should be considered unlikely.
Methods
Reagents
Dulbecco’s Modified Eagle’s Medium (DMEM), poly-D-
lysine (PDL), putrescine, thyroxin, tri-iodothyroxine,
progesterone, sodium selenite, papain, deoxyribonucle-
ase l, bovine serum albumin (BSA) fraction V, and insu-
lin were purchased from Sigma-Aldrich. L-glutamine,
0.25% trypsin-EDTA, and fetal bovine serum (FBS) were
purchased from Invitrogen/Life Technologies. MEM was
purchased from Gibco/Life Technologies. Holo-transferrin
(human) was purchased from EMD Millipore. Trypsin in-
hibitor was purchased from Roche Life Science. FGF-basic
and EGF were purchased from Peprotech. PDGF-AA was
purchased from R&D Systems Inc.
Animals
All experiments were approved by the University of
Manitoba Animal Care Committee. Sprague–Dawley
rats and wild type C57BL/6 mice were bred at the
Central Animal Care facility of the University of Manitoba.
Heterozygous PAR1 knockout mice (B6.129S4-F2rtm1Ajc/J)
on a C57Bl/6 background were purchased from Jackson
Laboratories (Stock Number: 002862). Animals were bred
to obtain homozygous PAR1 knockout mice. The genotype
of newborn mice was determined from tail samples.Genomic DNA was extracted using proteinase K in a DNA
digestion buffer. Polymerase chain reaction (PCR) was used
to detect PAR1 using the specific primers 5′GAC GTT
CAG AGG AAG GCT GA3′ (oIMR3504, Wild type), 5′
AAA ATG AAA GCG TCC TGC TG3′ (oIMR3503,
Common) and 5′TGG ATG TGG AAT GTG TGC
GAG3′ (oIMR8162, Mutant). PCR products were sepa-
rated by electrophoresis in a 2% agarose gel and stained
with Gelstar Nucleic Gel stain. The expected bands are
wild type = 175 base pairs (bp), mutant = 225 bp, and het-
erozygote = 175 bp / 225 bp.
Cultures of rat and mouse oligodendrocyte precursor
cells (OPC)
Rat OPC were cultured as previously described in detail
[7]. Mouse OPC cultures required some modifications
[43]. Wild-type mice were decapitated at 1-day age, the
brain was removed and stripped of meninges, the cere-
bral hemispheres (excluding hippocampus and basal
nuclei) were isolated, and cells were dissociated in
DMEM medium supplemented with 5000U penicillin
and streptomycin and Accutase cell detachment solution
(Millipore). Cells were washed and resuspended in DMEM
culture medium supplemented with 4 mM L-glutamine,
5000U penicillin and streptomycin, 20% heat inactivated
fetal bovine serum (FBS), 10 ng/ml basic fibroblast growth
factor (bFGF), 10 ng/ml epidermal growth factor (EGF)
and 5 ng/ml of platelet-derived growth factor (PDGF-AA)
then grown in lysine-coated flasks. On day 7–8, DMEM
medium with L-glutamine, penicillin and streptomycin,
20% FBS, and 10 ng/ml PDGF was used. Cultures were
kept at 37°C in humidified chamber with 5% CO2; the
media was changed every 3–4 days. OPCs were isolated
from the mixed glial culture by shaking on day 14–18.
Microglia were removed by allowing them to attach in a
plastic Petri dish. Floating OPCs were cultured on glass
coverslips in Sato’s serum-free modified medium, which
contained 20 ng/ml PDGF-AA, putrescine (Sigma P5780)
0.16 μg/ml, thyroxin (T4, Sigma T-1775) 4 ng/ml, tri-
iodothyroxine (T3, Sigma T-6397) 4 ng/ml, progester-
one (Sigma P8783) 0.66 ng/ml, bovine serum albumin
(BSA) fraction V (Sigma A4919) 1 μg/ml, L-glutamine
(GIBCO), human holotransferrin (Sigma T0665), Penstrep
(Invitrogen 15140), and insulin (Sigma I1882). In pilot
experiments (results not shown), oligodendrocyte lineage
was verified after 6 hours, 3 days, and 6 days by fixing
cells in cold methanol and 4% paraformaldehyde, fol-
lowed by immunofluorescence using primary antibodies
to A2B5 (mouse IgM; Millipore MAB312R), myelin basic
protein (MBP, rabbit IgG; Santa Cruz SC-13914), 2′3′-
cyclic-nucleotide 3′-phosphodiesterase (CNPase, mouse
IgG; Millipore MAB326), O4 (mouse IgM; Neuromics
MO15002), and glial fibrillary acidic protein (to exclude
astrocytes, rabbit IgG; Novocastra Z0334) and appropriate
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(DAPI; Sigma, D-8417) labeling of nuclei.
Cultured oligodendrocyte precursor cell (OPC) cell
death assays
We previously showed that plasma at 1:100 dilution had
a negative effect on OPC proliferation and caused cell
death detectable by both lactate dehydrogenase (LDH)
release and activation of caspase 3. Purified thrombin
at the calculated equivalent dose had a slightly greater
(although not statistically significant) adverse effect [7].
Adult mouse and rat blood were collected in EDTA-
coated tubes (to prevent blood clotting) and plasma was
isolated as previously described [7], then aliquoted and
stored at −20°C. When the thawed plasma is added to
Ca++-containing cell culture medium plasma enzyme ac-
tivity is normalized [44], although fibrinogen activity
might not be entirely restored [45]. Isolated OPCs from
rat and wild type C57Bl6 mice in serum-free Sato’s
culture medium were plated in 24-well plates with PDL-
coated glass coverslips (1×105 or 2×105 cells/well in dif-
ferent trials) and allowed to adhere. Four hours later the
media was changed to serum-free Sato’s medium with
added 10 μM bromodeoxyuridine (BrdU Sigma B-5002)
with or without added PAR1 antagonists SCH-79797
dihydrochloride (Tocris, Ellisville, MO, USA) or BMS-
200261 (Sigma). The dose range was based on previously
published work. SCH-79797 modulated the response of
cultured astrocytes to plasmin at a concentration of
5 μM [17] and thrombin-mediated cell death in hippo-
campal slices at 10 μM [18]. BMS-200261 blocked the
plasmin-induced rise of cytoplasmic Ca2+ in cultured
astrocytes at 1 μM [12], The cells were simultaneously
exposed to rat or mouse blood plasma (1:100, 1:250, and
1:1000 dilutions) for 24 h. Incorporated BrdU was de-
tected with monoclonal mouse anti-BrdU antibody (Cell
Signaling# 5292) and cells were counterstained with
DAPI. Cells were counted with a fluorescence micro-
scope using a 20x objective magnification. Prior to
fixation, 5 μl supernatant from OPC cultures was trans-
ferred to a 96-well plate, and 50 μl of the LDH cytotox-
icity detection kit II (Biovision) reaction mixture was
added. After 30 minutes absorbance was recorded at
450 nm using microplate reader. LDH concentration
was calculated in triplicate according to standards with
background subtraction. All rat OPC tests were repeated
in triplicate from separate cell isolations and all results
were read at 30 minutes and 3 hours. All mouse OPC
tests were done in duplicate. Data, expressed as mean ±
standard error of mean, were compared using ANOVA.
Autologous blood injection into neonatal mouse cerebrum
PAR1 mutant heterozygote mice mating typically yielded
2–3 neonates of each genotype (PAR1−/−, PAR1+/−,PAR1+/+) per litter. Mice were housed with their mothers.
As previously described [3,6], 1-day-old mice were anes-
thetized with 2% isoflurane, whole blood was obtained
from the tail and then was injected (15 μl though a 30
gauge needle) into the right periventricular region/
striatum. The injection coordinates were 1.5 mm lateral
to midline, 0.5 mm posterior to the outer canthus of the
eye, and 2.5 mm depth. Syringes contained no anticoagu-
lants and procedures were completed within 2 minutes
before the blood clotted. We previously showed that
serine protease activity due to thrombin and/or plasmin
is elevated at the edge of the resulting hematoma [6].
Additional controls included sham injected and intact
brain of all genotypes. Mice were killed by isoflurane
overdose followed by exsanguination and transcardiac
perfusion with cold 4% paraformaldehyde in phosphate
buffered saline 24 or 48 hours after blood injection.
The brains were removed, left overnight in the same
fixative, sliced in the coronal plane encompassing the
blood injection site, dehydrated, and embedded in par-
affin. Brains were assessed at 24 and 48 hours after
blood injection (3 genotypes × 2 time points × 2 condi-
tions; 3–4 per group).
Brain slices were sectioned serially at 5 μm thickness
and every 10th slide was stained with hematoxylin and
eosin (H&E) to identify the center of the injection site.
In previous similar experiments we determined in ad-
vance several exclusion criteria to be determined by
microscopic examination: 1) sham injections with blood
occupying the striatum or ventricle; 2) blood injections
with no obvious blood collections or hematoma not in-
volving the SVZ. In this experiment no exclusions were
mandated. Deparaffinized sections were treated using
heat-mediated antigen retrieval (0.1 M citrate buffer,
pH6, for 20 minutes) and endogenous peroxidase was
suppressed with 3% H2O2 in methanol for 10 minutes.
Sections were blocked with 10% goat serum in PBS. Im-
munohistochemical staining was used to detect reactive
astrocytes (rabbit anti-GFAP, 1:3000; Novocastra Z0334),
proliferating cells (rabbit anti-Ki67, 1:2000; Novocastra
Labs NCL 301103), and apoptotic cells (rabbit anti-
activated caspase-3, 1:250; Gene Tex GTX22302).
Microglia were detected with rabbit anti-Iba1 (1:2000;
Wako, Osaka, Japan 019–19741), and reactive changes
were evaluated by cell hypertrophy and increased cell
density in comparison to the contralateral side. Immuno-
reactive cells were revealed using biotinylated goat anti-
rabbit secondary (Jackson IR, 111-065-144) followed by
streptavidin/horseradish peroxidase (HRP; Jackson IR
016-030-084), and diaminobenzidine (DAB with 10 μL
30% H2O2). After hematoxylin counterstain, sections
were dehydrated and coverslipped.
The evaluator was blinded to the genotype. Immu-
noreactive cells and total cells were counted at 400x
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and contralateral to the injection site) using an ocular
counting grid. The subventricular zone (SVZ) between the
frontal horn of the lateral ventricle and the striatum and at
the angle of the frontal horn was evaluated in a 50×200 μm
rectangle and an approximately 200×200 μm triangular
area. Dorsal white matter above the ventricle was evalu-
ated in a 150×500 μm rectangular area. The number of
cells immunoreactive for each antigen was calculated and
the means were compared. For the Ki67, which had a nor-
mal distribution, we used ANOVA followed by Dunnett’s
method for comparison to controls without blood injec-
tion and Tukey-Kramer tests for comparison to matched
groups with blood injection. The caspase 3 and Iba1
values did not have normal distributions, therefore we used
the nonparametric Wilcoxon method to compare groups
(JMP10 software; SAS Institute, Cary NC). Differences
were considered significantly different at p < 0.05.
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